Clinical Trial Update: Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 bioequivalence study of olanzapine orally disintegrating tablets (5 mg) under fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine orodispersible tablet 5 mg (olanzapine)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Fasting | Phase 1 | Status: COMPLETED